Graphique simple
Calendrier avancé
Description Tema GLP-1 Obesity & Cardiometabolic ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.| Assets class size | Multi-Cap |
|---|---|
| Country | USA |
| Country ISO | US |
| Focus | Health Care |
| Issuer | Dawn Global Topco Ltd. |
| Region specific | Broad |
| Segment | Equity: Global Pharma, Biotech & Life Sciences |
| Strategy | Active |
| Валюта | usd |
| Годовая доходность | 27 |
| Дата основания | Nov 21. 2023 |
| Индекс | ACTIVE - No Index |
| Количество компаний | 10 |
| Комиссия | 0.75 |
| Полное наименование | Tema GLP-1 Obesity & Cardiometabolic ETF |
| Регион | Global |
| Сайт | lien |
| Средний P/E | 16.57 |
| Тип актива | Equity |
| Changement de prix par jour: | -2.32% (28.02) |
|---|---|
| Changement de prix par semaine: | -1.16% (27.69) |
| Changement de prix par mois: | -8.61% (29.95) |
| Changement de prix sur 3 mois: | -8.37% (29.87) |
| Changement de prix sur six mois: | -17.91% (33.34) |
| Evolution des prix depuis le début de l'année: | -5.49% (28.96) |
Payez votre abonnement
Plus de fonctionnalités et de données pour l'analyse des entreprises et des portefeuilles sont disponibles sur abonnement
